These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15262123)

  • 1. Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer.
    Xi Z; Kaern J; Davidson B; Klokk TI; Risberg B; Tropé C; Saatcioglu F
    Gynecol Oncol; 2004 Jul; 94(1):80-5. PubMed ID: 15262123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
    Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
    Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.
    Penson RT; Oliva E; Skates SJ; Glyptis T; Fuller AF; Goodman A; Seiden MV
    Gynecol Oncol; 2004 Apr; 93(1):98-106. PubMed ID: 15047220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
    Davidson B; Xi Z; Klokk TI; Tropé CG; Dørum A; Scheistrøen M; Saatcioglu F
    Am J Clin Pathol; 2005 Mar; 123(3):360-8. PubMed ID: 15716231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
    Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
    Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
    Fujii K; Takano M; Okamoto S; Sasaki N; Kita T; Kikuchi Y
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2141-4. PubMed ID: 15628759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
    Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.
    Loessner D; Quent VM; Kraemer J; Weber EC; Hutmacher DW; Magdolen V; Clements JA
    Gynecol Oncol; 2012 Dec; 127(3):569-78. PubMed ID: 22964375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
    Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells.
    Davidson B; Xi Z; Saatcioglu F
    Diagn Cytopathol; 2007 Feb; 35(2):80-4. PubMed ID: 17230566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
    Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
    Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients.
    Obiezu CV; Scorilas A; Katsaros D; Massobrio M; Yousef GM; Fracchioli S; Rigault de la Longrais IA; Arisio R; Diamandis EP
    Clin Cancer Res; 2001 Aug; 7(8):2380-6. PubMed ID: 11489816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
    Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
    ; Markman M; Blessing J; Rubin SC; Connor J; Hanjani P; Waggoner S
    Gynecol Oncol; 2006 Jun; 101(3):436-40. PubMed ID: 16325893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
    J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
    J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
    Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.